ILMN — Illumina, Inc.

Illumina Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $1.09 billion, up 4.8% year-over-year and 1.2% on an organic basis.
• Sequencing Consumables Revenue: $726 million, up 4% year-over-year, with clinical consumables growing 20% (excluding China).
• Gross Margin: Non-GAAP gross margin at 68.2%, up 80 basis points year-over-year.
• Operating Margin: Non-GAAP operating margin at 21.9%, expanding 150 basis points year-over-year.
• EPS: Non-GAAP diluted EPS of $1.15, a 19% increase year-over-year.
• Cash Flow: Cash flow from operations was $289 million, with free cash flow at $251 million.

2. Strategic Updates and Business Highlights

• Clinical Market Strength: Clinical markets accounted for over 65% of sequencing consumables revenue, driven by increased adoption of sequencing-based diagnostics.
• NovaSeq X Performance: Over 80 NovaSeq X instruments placed in Q1, exceeding expectations and contributing to strong consumables growth.
• SomaLogic Acquisition: Successfully integrated, performing in line with expectations.
• Product Innovations: Launched TruPath for whole genome sequencing and expanded offerings in spatial transcriptomics, enhancing the value of the NovaSeq X platform.
• R&D Focus: Continued investment in proteomics and single-cell technologies, with a roadmap for new flow cells and improvements in data quality.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised to $4.52 billion to $4.62 billion for 2026, reflecting Q1 outperformance.
• Operating Margin Guidance: Increased to 23.4% to 23.6%, indicating continued margin expansion.
• EPS Guidance: Updated to $5.15 to $5.30, representing a 12% growth at the midpoint.
• Q2 Expectations: Anticipated revenue of $1.12 billion to $1.14 billion, with non-GAAP EPS of $1.20 to $1.25.

4. Bad News, Challenges, or Points of Concern

• Research Market Caution: Research and applied markets are expected to decline mid- to high single digits due to funding uncertainties, despite some signs of stabilization.
• Inflationary Pressures: Facing headwinds from increased costs related to components and freight, which may impact margins in the short term.
• Competitive Landscape: Concerns about new entrants and pricing pressures in the market, particularly with competitors launching lower-cost sequencing options.

5. Notable Q&A Insights

• Guidance Adjustments: Analysts questioned why organic growth guidance wasn't raised despite strong Q1 results. Management indicated cautious optimism and a desire to maintain a conservative outlook.
• Clinical vs. Research Demand: Clinical placements are strong, while research remains cautious. Management expects a return to growth in research as funding stabilizes.
• NovaSeq X Demand: The increase in NovaSeq X placements is driven by customer confidence in ongoing innovation and the potential for consumables revenue, despite some pricing discounts for bulk orders.
• Operating Margin Projections: Management indicated that inflationary pressures are being addressed through various mitigating actions, with expectations for margin improvement in the second half of the year.

Overall, Illumina's Q1 2026 results reflect a strong start to the year, driven by clinical market strength and robust demand for the NovaSeq X platform, while navigating challenges in the research sector and inflationary pressures.